Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.52 |
| ▸ | TGM2 | P21980 | 9/20 | 0.52 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TGM1 | P22735 | 1/20 | 0.47 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.45 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.45 |
| ▸ | KCNQ5 | Q9NR82 | 4/20 | 0.45 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.45 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28534540 | 0.77 | TGM2 (0.56) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL21585659 | 0.76 | TGM2 (0.55) | BTKTGM2F13A1LMNATGM1 | |
| SCHEMBL25413921 | 0.75 | KCNQ3 (0.50) | KCNQ3KCNQ2KCNQ5KCNE1KCNQ1 | |
| SCHEMBL19776473 | 0.75 | KCNQ3 (0.50) | KCNQ3KCNQ2KCNQ5KCNE1KCNQ1 | |
| SCHEMBL3548542 | 0.75 | BTK (0.49) | BTK | |
| SCHEMBL17593382 | 0.74 | NPC1 (0.52) | LMNAKCNQ3KCNQ2KCNQ5KCNE1 | |
| SCHEMBL9931618 | 0.74 | KCNQ3 (0.49) | LMNAKCNQ3KCNQ2KCNQ5KCNE1 | |
| SCHEMBL1381911 | 0.72 | TGM2 (0.66) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL19911202 | 0.72 | TGM2 (0.53) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL439369 | 0.72 | TGM2 (0.79) | TGM2F13A1LMNATGM1TGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205307-B2 | Pyrimidines as novel openers of potassium ion channels | ICAGEN, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20030181465-A1 | Pyrimidines as novel openers of potassium ion channels | ICAGEN, INC. | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181465-A1 | Pyrimidines as novel openers of potassium ion channels | KCNJ1, KCNJ2, KCNJ11 | BTK 4029/4885TGM2 3529/4885F13A1 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.